Sponsor

Ono Pharmaceutical Co., Ltd.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Ono Pharmaceutical Co., Ltd. appears in 46 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials46
Recruiting shown3
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

46 shown
A Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes MellitusNCT07619157 · lead sponsor · 2026-06-02
RECRUITING
A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)NCT07169708 · lead sponsor · 2026-03-20
RECRUITING
A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease DementiaNCT06803823 · lead sponsor · 2025-05-01
RECRUITING
A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)NCT07825402 · lead sponsor · 2027-01-01
NOT_YET_RECRUITING
ONO-4915 in Patients With Primary Sjogren's DiseaseNCT07823790 · lead sponsor · 2026-10-01
NOT_YET_RECRUITING
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's DiseaseNCT06881836 · lead sponsor · 2025-04-24
ACTIVE_NOT_RECRUITING
A Study of ONO-1110 in Patients With Major Depressive DisorderNCT06792136 · lead sponsor · 2025-01-16
COMPLETED
Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly PaclitaxelNCT06538272 · lead sponsor · 2023-08-31
COMPLETED
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast CancerNCT06570031 · lead sponsor · 2021-11-09
COMPLETED
Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung CancerNCT06525246 · lead sponsor · 2021-08-06
COMPLETED
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung CancerNCT06542731 · lead sponsor · 2021-06-01
ACTIVE_NOT_RECRUITING
Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)NCT03117049 · lead sponsor · 2017-06-13
COMPLETED
ONO-4538 Study in Patients With Advanced Non-Small Cell Lung CancerNCT02582125 · lead sponsor · 2016-01-27
COMPLETED
ONO-4538 Study in Patients With Advanced Non-Small Cell Lung CancerNCT02175017 · lead sponsor · 2014-06-01
COMPLETED
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)NCT02083289 · lead sponsor · 2014-05-01
COMPLETED
MK-0431/ONO-5435 Phase III Clinical Trial - Insulin Add-on Study for Patients With Type 2 Diabetes MellitusNCT00854035 · lead sponsor · 2009-02-01
COMPLETED
A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)NCT00694941 · lead sponsor · 2008-06-01
COMPLETED
Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT00403104 · lead sponsor · 2006-11-01
COMPLETED
Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes MellitusNCT00363519 · lead sponsor · 2006-08-01
COMPLETED
Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes MellitusNCT00363948 · lead sponsor · 2006-08-01
COMPLETED
Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes MellitusNCT00363844 · lead sponsor · 2006-08-01
COMPLETED
Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in JapanNCT00212693 · lead sponsor · 2004-01-01
COMPLETED
MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 DiabetesNCT01517321 · lead sponsor
COMPLETED
Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung CancerNCT03090737 · collaborator · 2017-06-02
COMPLETED
Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's SyndromeNCT03100942 · collaborator · 2017-05-01
COMPLETED
A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in JapanNCT03273790 · collaborator · 2017-04-01
COMPLETED
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) TherapyNCT02864251 · collaborator · 2017-03-17
COMPLETED
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)NCT02998528 · collaborator · 2017-03-04
COMPLETED
Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice SettingsNCT02758769 · collaborator · 2016-06-07
COMPLETED
Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer PatientsNCT02946671 · collaborator · 2016-03-01
COMPLETED
Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)NCT02626026 · collaborator · 2016-01-26
COMPLETED
An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based ChemotherapyNCT02538666 · collaborator · 2015-10-13
COMPLETED
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung CancerNCT02481830 · collaborator · 2015-09-14
COMPLETED
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)NCT02477826 · collaborator · 2015-08-05
COMPLETED
DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in JapanNCT02226822 · collaborator · 2014-09-20
COMPLETED
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)NCT02041533 · collaborator · 2014-03-27
COMPLETED
Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mgNCT02600468 · collaborator · 2013-09-01
COMPLETED
Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mLNCT02600455 · collaborator · 2013-09-01
COMPLETED
Abatacept Post-marketing Clinical Study in JapanNCT01758198 · collaborator · 2013-04-11
COMPLETED
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)NCT01614886 · collaborator · 2012-07-01
COMPLETED
A Placebo and Active Controlled Study of ONO-6950 Following Allergen Challenge in Patients With AsthmaNCT01551147 · collaborator · 2012-06-01
COMPLETED
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase InhibitorsNCT01529619 · collaborator · 2012-03-01
COMPLETED
A Placebo and Active Controlled Study of ONO-6950 in Asthmatic PatientsNCT01536041 · collaborator · 2012-03-01
COMPLETED
Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)NCT01226745 · collaborator · 2010-10-01
TERMINATED
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent MalignanciesNCT00730639 · collaborator · 2008-10-30
COMPLETED
Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's DiseaseNCT00423085 · collaborator · 2007-01-01
COMPLETED

Drugs studied in this sponsor's trials

22 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Ono Pharmaceutical Co., Ltd. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo13
carboplatin5
cisplatin4
paclitaxel4
pemetrexed4
gemcitabine3
sitagliptin phosphate3
docetaxel2
placebo RxCUI 8375 · Lead sponsor in 9 linked trial(s) · 2 currently recruiting 13 trials carboplatin RxCUI 40048 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 5 trials cisplatin RxCUI 2555 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 4 trials paclitaxel RxCUI 56946 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 4 trials pemetrexed RxCUI 68446 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 4 trials gemcitabine RxCUI 12574 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 3 trials sitagliptin phosphate RxCUI 621590 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials docetaxel RxCUI 72962 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials montelukast RxCUI 88249 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials nivolumab RxCUI 1597876 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials Orencia RxCUI 616011 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials abemaciclib RxCUI 1946825 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial bevacizumab RxCUI 253337 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial ipilimumab RxCUI 1094833 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial latanoprost RxCUI 43611 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial letrozole RxCUI 72965 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial methotrexate RxCUI 6851 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial osimertinib mesylate RxCUI 1721559 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial palbociclib RxCUI 1601374 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial ramucirumab RxCUI 1535922 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial topotecan RxCUI 57308 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial vinorelbine RxCUI 39541 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

collaborator23
lead sponsor23
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.